Last quarter (Q4 2023), Panbela Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Panbela Therapeutics's net income was $-6.49M. See Panbela Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 13.26M	$ 25.65M	$ 34.09M	$ 10.01M	$ 5.75M	$ 4.32M
Operating Income	$ -13.26M	$ -25.65M	$ -34.09M	$ -10.01M	$ -5.75M	$ -4.32M
Net Non Operating Interest Income Expense	$ -349.00K	$ -194.00K	$ -274.00K	$ -11.00K	$ -17.00K	$ -2.19M
Other Income Expense	$ -983.00K	$ -392.00K	$ 682.00K	$ 602.00K	$ 708.00K	$ -99.00K
Pretax Income	$ -22.35M	$ -25.45M	$ -35.05M	$ -10.62M	$ -5.06M	$ -6.62M
Tax Provision	$ -180.00K	$ -186.00K	$ -116.00K	$ -488.00K	$ -295.00K	$ -415.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -12.45M	$ -25.26M	$ -34.93M	$ -10.13M	$ -4.77M	$ -6.20M
Basic EPS	$ -88.01	$ -316.52	$ -67.91	-	$ -0.62	$ -1.09
Diluted EPS	$ -22.09	$ -316.52	$ -67.91	$ -26.10	$ -0.62	$ -1.09
Basic Average Shares	$ 9.31M	$ 108.69K	$ 514.37K	$ 390.30K	$ 7.73M	$ 5.70M
Diluted Average Shares	$ 8.79M	$ 108.69K	$ 514.37K	$ 390.30K	$ 7.73M	$ 5.70M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 13.26M	$ 25.65M	$ 34.09M	$ 10.01M	$ 5.75M	$ 4.32M
Net Income From Continuing And Discontinued Operation	$ -22.17M	$ -25.26M	$ -34.93M	$ -10.13M	$ -4.77M	$ -6.20M
Normalized Income	$ -6.53M	$ -25.64M	-	-	$ -4.87M	$ -6.20M
Interest Expense	-	-	-	-	$ 17.00K	$ 2.19M
EBIT	$ -21.94M	$ -25.13M	$ -34.76M	$ -10.61M	$ -5.05M	$ -4.42M
EBITDA	$ -21.70M	$ -24.89M	$ -34.76M	$ -10.61M	$ -5.05M	$ -4.42M

Currency in USD

Panbela Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing